New pneumococcal conjugate vaccines from Pfizer Inc. and Merck & Co., Inc. and use of GlaxoSmithKline plc’s herpes zoster vaccine Shingrix in immunocompromised adults sailed through the Center for Disease Control and Prevention’s Advisory Committee on Immunization Practices on 20 October, resulting in three unanimous votes to recommend use of vaccines.
ACIP has been holding to a swift pace of non-COVID-19 vaccine assessments despite the tremendously increased workload before the committee...







